Clinical Trials
10 trialsNCT06157892 2026-05-05
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen Inc.
Phase 2 Recruiting
NCT05458674 2026-04-03
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Criterium, Inc.
Phase 2 Recruiting
NCT04539938 2026-03-23
HER2CLIMB-04
Seagen Inc.
Phase 2 Completed
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT04721977 2026-01-09
MK-7119-001
Pfizer
Phase 2 Active not recruiting
NCT04579380 2025-12-19
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen Inc.
Phase 2 Active not recruiting
NCT04632992 2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2 Completed
NCT03043313 2024-11-26
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
Seagen Inc.
Phase 2 Completed
NCT02614794 2023-08-14
HER2CLIMB
Seagen Inc.
Phase 2 Completed
NCT05190445 2022-09-08
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
Pieris Pharmaceuticals, Inc.
Phase 2 Active not recruiting